HROW Harrow, Inc. - Common Stock
NASDAQ · Pharmaceuticals · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 10, 2026HROW Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
HROW Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
| Ex-Datum | Split | Typ |
|---|---|---|
| 8. Februar 2013 | 1-for-5 | Umgekehrt |
| 24. Februar 2012 | 1-for-8 | Umgekehrt |
Über Harrow, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.
Administration and drug pricing advocacy
The company's founder and chief executive officer is Mark L. Baum, a lawyer by training. Baum has been working in the HIV-related pharmacy field since 1999. Baum has been an advocate for drug pricing and patient advocacy, debating former US congressman James Greenwood on this issue at the Oxford Union debating society. In 2016, Baum authored a monograph on drug pricing and has written about pharmaceutical market monopolies in The Wall Street Journal.
Harrow, through its ImprimisRx subsidiary, has sought to create competition for drugs that companies have monopolies through regulatory or other means by marketing new formulations as a compounding pharmacy. This strategy would allow patient access to certain lower cost medication provided, among other conditions, a patient's physician believed such a formulation was best suited for a patient's needs.
In 2015, the company gained international attention when it compounded a pyrimethamine and leucovorin combination formulation which it argued may offer a low-cost, US$1 per pill, "alternative" to Daraprim, a medication which gained public attention after its price in the United States was increased by over 5,000 percent by Martin Shkreli and Turing Pharmaceuticals. In December 2015, Express Scripts accepted the company's product into its formulary.
In 2016, it introduced a lower cost version of tiopronin, and was said to have been working on a version of Mylan's EpiPen. The EpiPen competitor's price target was US$100 for a pair of injectors.
In October 2015, Anthony Principi, a former United States Secretary of Veterans Affairs, was elected to the company's board of directors.
ImprimisRx compounding business
Through its compounding subsidiary ImprimisRx, the company was the first pharmaceutical compounding company to make cGMP ophthalmic eye drops and other sterile compounded products available at a national scale through its FDA-registered outsourcing facility.
ImprimisRx's primary business is that of compounding drugs; that is, combining or altering the formulation of existing drugs to market them to specific populations. As of 2015, the company's business model was driven by development and sale of inexpensive alternatives to off-patent medicines where there was previously only a single manufacturer who could therefore charge outsize prices.
In August 2020, ImprimisRx announced that it was expanding its business beyond compounded drugs and that through a partnership with EyePoint Pharmaceuticals, it would begin to sell Dexycu, an FDA-approved steroid product.
As of 2020, Imprimis operated two pharmaceutical production and distribution facilities, both of which are located in Ledgewood, New Jersey. The company has licenses to operate federally, through the US DEA, and through state pharmacy boards in all 50 of the United States.
Litigation
In 2017, after launching a $49 per month low-cost compounded cyclosporine-A formulation as a potential competitor to Restasis and a glaucoma eye drop program called Simple Drops, the company, alongside Sinceres, became the target of a suit from Allergan for claims connected to supposed false and misleading marketing statements.
The company responded, calling Allergan a "professional litigant" and stating, "Allergan, one of the most powerful Big Pharma companies in the world, has filed this lawsuit against one of the smallest pharmaceutical companies in the world, to snuff out any competition to its high drug price strategies. Allergan, a true Goliath, is bent on ensuring that Americans continue to pay the highest possible prices for its drugs."
During the lawsuit, it was revealed that Allergan engaged in significant lobbying to FDA, state boards of pharmacy, and other federal and state agencies to complain about ImprimisRx. In December 2017, ImprimisRx received a warning letter from the FDA, relaying the agency's determination that the marketing of some of the company's eye drops contained false or misleading claims about efficacy and risks, allegedly in violation of federal law.
After a jury trial, Harrow (then Imprimis Pharmaceuticals) was ordered to pay $0 for disgorgement of profit and $48,500 for lost profit, despite Allergan having sought $60 million.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | HROW | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -31.45-Jahres-Durchschnitt ≈-115.6 | ≈-115.6 | · | · | |
| P/S (TTM) | 4.15-Jahres-Durchschnitt ≈4.8 | ≈4.8 | · | · | |
| K/B (MRQ) | 75.25-Jahres-Durchschnitt ≈18.8 | ≈18.8 | 3.2 | Überbewertet | |
| Kurs / FCF (TTM) | 227.85-Jahres-Durchschnitt ≈-53.3 | ≈-53.3 | · | · | |
| Kurs / Cashflow (TTM) | 182.75-Jahres-Durchschnitt ≈79.0 | ≈79.0 | · | · | |
| Kurs / Materieller Buchwert (MRQ) | -7.1 | · | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | HROW | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Bruttogewinnmarge (TTM) | 73.3%5-Jahres-Durchschnitt ≈73.2% | ≈73.2% | · | · | |
| Betriebsgewinnmarge (TTM) | -1.00%5-Jahres-Durchschnitt ≈4.1% | ≈4.1% | 2.2% | Schwach | |
| EBITDA Margin (EBITDA-Marge) | 11.7%5-Jahres-Durchschnitt ≈5.2% | ≈5.2% | 2.4% | Schwach | |
| Vorgewinnmarge (TTM) | -12.1%5-Jahres-Durchschnitt ≈-13.6% | ≈-13.6% | 9.0% | Schwach | |
| Nettogewinnmarge (TTM) | -13.5%5-Jahres-Durchschnitt ≈-14.0% | ≈-14.0% | 4.5% | Schwach | |
| ROA (TTM) | -9.8%5-Jahres-Durchschnitt ≈-10.2% | ≈-10.2% | -0.40% | Unterdurchschnittlich | |
| ROE (TTM) | -114.8%5-Jahres-Durchschnitt ≈-49.8% | ≈-49.8% | -3.7% | Unterdurchschnittlich | |
| ROIC | 218.6%5-Jahres-Durchschnitt ≈50.7% | ≈50.7% | 7.9% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | HROW | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 2.25-Jahres-Durchschnitt ≈3.9 | ≈3.9 | 4.0 | Geringe Liquidität | |
| Quick Ratio | 1.95-Jahres-Durchschnitt ≈2.3 | ≈2.3 | 2.6 | Unterdurchschnittlich |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | HROW | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 36.4%5-Jahres-Durchschnitt ≈41.4% | ≈41.4% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 45.4%5-Jahres-Durchschnitt ≈41.4% | ≈41.4% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 41.0% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | HROW | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.75-Jahres-Durchschnitt ≈0.7 | ≈0.7 | 0.7 | Spitzenklasse | |
| Inventory Turnover (Lagerumschlag) | 5.65-Jahres-Durchschnitt ≈4.8 | ≈4.8 | 2.1 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 2.45-Jahres-Durchschnitt ≈9.6 | ≈9.6 | 5.1 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$730.0K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 11, 2026 | $-0.46 | $-0.18 | -150.5% |
| 31. März 2026 | Mai 7, 2026 | $-0.74 | $-0.41 | -80.7% |
| 31. Dezember 2025 | $0.17 | $0.38 | -54.8% | |
| 30. September 2025 | $0.22 | $0.27 | -18.1% | |
| 30. Juni 2025 | $0.13 | $0.01 | — | |
| 31. März 2025 | $-0.50 | $-0.05 | -970.7% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Cost of Revenue | $68M | $49M | $40M | $25M | $18M | $14M | $17M | $17M | $14M | · | · | · | |
| Gross Profit | $204M | $150M | $91M | $63M | $54M | $34M | $34M | $25M | $13M | $10M | $5M | $567.0K | |
| R&D Expense | $21M | $12M | $7M | $3M | $11M | $2M | $2M | $825.0K | $413.0K | $739.0K | $332.0K | $237.0K | |
| SG&A Expense | $153M | $129M | $83M | $58M | $41M | $31M | $33M | $29M | $25M | $18M | $13M | $8M | |
| Operating Expenses | $174M | $142M | $90M | $61M | $53M | $34M | $39M | $30M | $25M | · | · | · | |
| Operating Income | $31M | $9M | $431.0K | $2M | $2M | $385.0K | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M | |
| Interest Expense | · | · | $21M | $7M | $5M | · | · | · | · | · | · | $3.8K | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | $32.4K | |
| Other Non-op | $47.0K | $-185.0K | $-444.0K | $102.0K | $197.0K | $-73.0K | $630.0K | $103.0K | $-884.0K | $2M | $-1M | $29.0K | |
| Pretax Income | $-1M | $-17M | $-24M | $-14M | $-18M | $-3M | $-117.0K | $15M | $-13M | $-19M | · | · | |
| Income Tax | $4M | $161.0K | $701.0K | $75.0K | $133.0K | $4.0K | $8.0K | · | $-935.0K | $-111.0K | · | $3.0K | |
| Net Income | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| EPS (Basic) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 | $-0.13 | $0.01 | $0.67 | $-0.60 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · | |
| Shares (Basic) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | 26,757,451 | 25,895,352 | 25,323,159 | 21,917,570 | 20,027,712 | · | · | · | |
| Shares (Diluted) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | · | 25,895,352 | 26,466,098 | 23,812,045 | 20,027,712 | · | · | · | |
| EBITDA | $32M | $10M | $1M | $3M | $3M | $2M | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $73M | $47M | $74M | $96M | $42M | $4M | $5M | · | $4M | $9M | $3M | $8M | |
| Short-term Investments | · | · | $9M | $6M | $9M | $28M | · | · | · | · | · | · | |
| Receivables | $111M | $116M | $36M | $6M | $4M | $3M | $2M | $2M | $2M | $3M | $840.0K | $81.0K | |
| Inventory | $14M | $11M | $11M | $7M | $4M | $4M | $3M | $2M | $2M | $2M | $1M | $373.0K | |
| Prepaid Expense | $14M | $15M | $10M | $4M | $1M | $2M | $586.0K | $837.0K | $714.0K | $938.0K | $786.0K | $241.0K | |
| Other Current Assets | $2M | $3M | $2M | $118.0K | $92.0K | $190.0K | $105.0K | $125.0K | $124.0K | $106.0K | $119.0K | $35.0K | |
| Current Assets | $212M | $190M | $139M | $118M | $61M | $41M | $36M | $33M | $9M | $15M | $6M | $9M | |
| PP&E (Net) | $3M | $4M | $4M | $3M | $3M | $4M | $5M | $6M | $6M | $7M | $3M | $243.0K | |
| PP&E (Gross) | $15M | $15M | $14M | $13M | $11M | $10M | $11M | $11M | $9M | $9M | $3M | $288.0K | |
| Accum. Depreciation | $12M | $11M | $10M | $9M | $8M | $6M | $5M | $4M | $3M | $1M | $300.0K | $45.0K | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $2M | $2M | $2M | $2M | $332.0K | |
| Intangibles | $175M | $185M | $160M | $24M | $16M | $2M | $2M | $3M | $3M | $3M | $3M | $611.0K | |
| Total Assets | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Accounts Payable | $35M | $39M | $25M | $14M | $6M | $4M | $8M | $6M | $4M | $4M | $3M | $787.0K | |
| Short-term Debt | · | $220M | · | · | · | $4M | $2M | $3M | · | $4M | · | · | |
| Current Liabilities | $96M | $91M | $49M | $19M | $10M | $11M | $12M | $12M | $6M | $10M | $5M | $2M | |
| Capital Leases | $8M | $9M | $7M | $7M | $6M | $7M | $6M | · | $720.0K | $1M | $1.0K | $19.0K | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $936.0K | $1M | · | |
| Total Liabilities | $347M | $320M | $242M | $130M | $87M | $31M | $32M | $25M | $21M | $21M | $16M | $2M | |
| Long-term Debt | $250M | $263M | $247M | $152M | $103M | $20M | · | $23M | $23M | · | · | · | |
| Total Debt | · | · | · | · | · | $3M | $2M | $3M | · | $4M | · | · | |
| Common Stock | $37.0K | $35.0K | $35.0K | $30.0K | $27.0K | $26.0K | $26.0K | $24.0K | $21.0K | $19.0K | $10.0K | $9.0K | |
| Paid-in Capital | $209M | $221M | $205M | $137M | $107M | $105M | $102M | $99M | $91M | $83M | · | · | |
| Retained Earnings | $-157M | $-151M | $-134M | $-109M | $-95M | $-77M | $-74M | $-74M | $-89M | $-77M | $-58M | $-42M | |
| Stockholders' Equity | $52M | $70M | $71M | $28M | $11M | $27M | $28M | $25M | $3M | $6M | $-1M | $8M | |
| Liabilities + Equity | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Shares Outstanding | 37,229,159 | 35,622,214 | 35,168,260 | 29,901,530 | 26,902,763 | 25,749,875 | 25,526,931 | 24,339,610 | 20,623,129 | 18,627,915 | 9,755,678 | 9,258,231 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | $1M | $255.0K | $37.0K | |
| Stock-based Comp | $13M | $18M | $16M | $8M | $6M | $3M | $2M | $2M | $3M | $4M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $-935.0K | $-111.0K | · | · | |
| Amort. of Intangibles | $17M | $12M | $10M | $2M | $161.0K | $167.0K | $209.0K | $235.0K | $364.0K | $351.0K | $355.0K | $48.0K | |
| Other Non-cash | $35M | $-24M | $12M | $7M | $16M | $-2M | · | · | · | · | · | · | |
| Operating Cash Flow | $44M | $-22M | $4M | $2M | $5M | $-1M | $950.0K | $687.0K | $-9M | $-11M | $-11M | $-7M | |
| CapEx | $887.0K | $2M | $1M | $3M | $2M | $862.0K | $1M | $2M | $772.0K | $7M | $-995.0K | $174.0K | |
| Investing Cash Flow | $-5M | $-33M | $-153M | $-2M | $-19M | $-981.0K | $-2M | $-2M | $-961.0K | $-7M | $-5M | $-910.0K | |
| Stock Issued | · | · | $65M | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $-13.0K | |
| Net Stock Activity | · | · | · | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | $-13.1K | |
| Financing Cash Flow | $-13M | $29M | $127M | $54M | $51M | $1M | $-1M | $4M | $5M | $25M | $11M | $599.0K | |
| Net Change in Cash | $26M | $-27M | $-22M | $54M | $38M | $-648.0K | $-2M | $3M | $-5M | $6M | $-6M | $-7M | |
| Taxes Paid | $93.0K | $374.0K | · | $75.0K | $11.0K | $4.0K | $17.0K | $4.0K | $9.0K | $9.0K | $1.0K | $1.0K | |
| Free Cash Flow | $43M | $-24M | $2M | $-892.0K | $3M | $-2M | $-518.0K | $-1M | $-10M | $-4M | $-12M | $-7M | |
| Levered FCF | · | · | $-20M | $-8M | · | · | · | · | · | · | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% | 70.4% | 67.3% | 60.1% | 49.6% | 50.7% | 46.4% | 34.2% | |
| Operating Margin | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% | 0.79% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| Net Margin | -1.9% | -8.8% | -18.8% | -15.9% | -24.9% | -6.9% | 0.33% | 35.4% | -44.8% | -95.7% | -163.6% | -609.4% | |
| Pretax Margin | -0.50% | -8.7% | -18.2% | -15.8% | -24.7% | -7.0% | -0.24% | 35.4% | -48.3% | · | · | · | |
| EBITDA Margin | 11.7% | 5.1% | 1.1% | 3.6% | 4.4% | 4.6% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| ROA | -1.3% | -5.0% | -10.4% | -11.0% | -23.1% | -5.8% | 0.31% | 39.9% | -46.9% | -92.3% | -130.5% | -77.8% | |
| ROE | -8.4% | -24.9% | -49.6% | -72.5% | -93.6% | -12.2% | 0.64% | 117.8% | -265.0% | -756.4% | -470.0% | -87.0% | |
| ROIC | 218.6% | 12.8% | 0.63% | 7.0% | 14.4% | 1.3% | · | · | -431.5% | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 | 3.7 | 3.0 | 2.8 | 1.5 | 1.5 | 1.1 | 5.8 | |
| Quick Ratio | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 | 0.6 | 0.2 | 0.2 | 1.0 | 1.2 | 0.7 | 5.3 | |
| Debt / Equity | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | 0.6 | · | · | |
| Interest Coverage | · | · | 0.0 | 0.3 | · | · | · | · | · | · | · | -2670.2 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.6 | 0.6 | 0.7 | 0.9 | 0.8 | 0.9 | 1.1 | 1.0 | 1.0 | 0.8 | 0.1 | |
| Inventory Turnover | 5.6 | 4.6 | 4.6 | 4.7 | 4.5 | 4.0 | 6.5 | 8.1 | · | · | · | · | |
| Receivables Turnover | 2.4 | 2.6 | 6.1 | 16.5 | 20.3 | 20.9 | 26.1 | 24.0 | 12.0 | 10.6 | 21.1 | 40.8 |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.41 | $1.96 | $2.01 | $0.92 | $0.42 | $1.06 | $1.09 | $1.02 | $0.13 | $0.35 | $-0.14 | $0.88 | |
| Revenue / Share | $7.41 | $5.60 | $3.99 | · | · | $1.89 | $1.93 | $1.74 | · | · | · | · | |
| Cash Flow / Share | $1.19 | $-0.62 | $0.12 | · | · | $-0.04 | $0.04 | $0.03 | · | · | · | · | |
| Cash / Share | $1.96 | $1.33 | $2.11 | · | $1.57 | $0.16 | · | · | $0.19 | $0.48 | $0.28 | $0.89 | |
| EPS (TTM) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 36.4% | 53.3% | 46.9% | 22.2% | 48.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 45.4% | 40.2% | 38.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 41.0% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Net Income TTM | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| Market Cap | $1.82B | $1.20B | $394M | $441M | $232M | $177M | $199M | $138M | $35M | $47M | $68M | $69M | |
| Enterprise Value | · | · | · | · | · | $175M | · | · | · | $42M | · | · | |
| P/E | -350.0 | -68.5 | -14.9 | -28.9 | · | -52.8 | 778.0 | 9.3 | -2.8 | · | · | · | |
| P/S | 6.7 | 6.0 | 3.0 | 5.0 | 3.2 | 3.6 | 3.9 | 3.3 | 1.3 | 2.3 | 7.0 | 41.8 | |
| P/B | 34.8 | 17.2 | 5.6 | 16.0 | 20.6 | 6.5 | 7.2 | 5.6 | 13.4 | 7.2 | -48.8 | 8.5 | |
| P / Tangible Book | · | · | · | 124.7 | · | 7.1 | · | · | · | · | · | · | |
| P / Cash Flow | 41.6 | -53.8 | 102.6 | 258.9 | 45.7 | -160.6 | 209.1 | 201.6 | -4.0 | -4.2 | -6.1 | -9.8 | |
| P / FCF | 42.4 | -50.2 | 165.5 | -494.8 | 70.5 | -90.0 | -383.4 | -128.1 | -3.7 | -10.8 | -5.6 | -9.6 | |
| EV / EBITDA | · | · | · | · | · | 77.3 | · | · | · | -2.6 | · | · | |
| EV / FCF | · | · | · | · | · | -89.3 | · | · | · | -9.6 | · | · | |
| EV / Revenue | · | · | · | · | · | 3.6 | · | · | · | 2.1 | · | · | |
| Earnings Yield | -0.29% | -1.5% | -6.7% | -3.5% | · | -1.9% | 0.13% | 10.7% | -35.3% | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71M | $44M | $89M | $72M | $64M | $48M | $67M | $49M | $49M | $35M | $36M | $34M | $33M | $26M | $20M | $23M | |
| Cost of Revenue | $20M | $17M | $18M | $18M | $16M | $16M | $14M | $12M | $13M | $11M | $11M | $10M | $10M | $8M | $6M | $7M | |
| Gross Profit | $50M | $27M | $71M | $54M | $48M | $32M | $53M | $37M | $36M | $24M | $25M | $24M | $23M | $18M | $14M | $16M | |
| R&D Expense | $8M | $6M | $12M | $3M | $3M | $3M | $5M | $2M | $3M | $2M | $3M | $1M | $1M | $734.0K | $703.0K | $775.0K | |
| SG&A Expense | $53M | $43M | $43M | $36M | $33M | $41M | $35M | $34M | $32M | $29M | $26M | $21M | $20M | $16M | $15M | $15M | |
| Operating Expenses | $61M | $49M | $55M | $39M | $36M | $44M | $40M | $36M | $35M | $31M | $30M | $22M | $21M | $17M | $16M | $16M | |
| Operating Income | $-11M | $-22M | $16M | $15M | $11M | $-11M | $13M | $1M | $2M | $-7M | $-5M | $2M | $2M | $1M | $-2M | $-94.0K | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $5M | · | $6M | $6M | $5M | $2M | $2M | |
| Other Non-op | $0 | · | $7M | $61.0K | $-6.0K | $-7M | $6M | $4.0K | $46.0K | $-7M | $-100.0K | $-195.0K | $-178.0K | $29.0K | · | · | |
| Pretax Income | $-17M | $-28M | $10M | $1M | $5M | $-18M | $6M | $-4M | $-6M | $-14M | $-10M | $-3M | $-4M | $-7M | $1M | $-6M | |
| Income Tax | $0 | $25.0K | · | · | $0 | · | $-514.0K | $20.0K | $655.0K | · | $-535.0K | $2M | $-15.0K | $-288.0K | $0 | $35.0K | |
| Net Income | $-17M | $-28M | $7M | $1M | $5M | $-18M | $7M | $-4M | $-6M | $-14M | $-9M | $-4M | $-4M | $-7M | $1M | $-6M | |
| EPS (Basic) | $-0.46 | $-0.74 | $0.19 | $0.03 | $0.14 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| EPS (Diluted) | $-0.46 | $-0.74 | $0.20 | $0.03 | $0.13 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| Shares (Basic) | 37,350,401 | 37,231,321 | · | 37,145,440 | 36,790,306 | 35,826,452 | · | 35,702,200 | 35,618,977 | 35,469,638 | · | 34,255,197 | 30,458,677 | 30,289,730 | · | 27,349,642 | |
| Shares (Diluted) | 37,350,401 | 37,231,321 | · | 38,875,005 | 38,853,855 | 35,826,452 | · | 35,702,200 | 35,618,977 | 35,469,638 | · | 34,255,197 | 30,458,677 | 30,289,730 | · | 27,349,642 | |
| EBITDA | $-11M | $-22M | · | $15M | $12M | $-11M | · | $1M | $2M | $-7M | · | $2M | $2M | $1M | · | $-94.0K |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84M | $95M | $73M | $74M | $53M | $67M | $47M | $73M | $71M | $69M | · | $66M | · | · | $96M | $45M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | $7M | · | $8M | $7M | $8M | $6M | $4M | |
| Receivables | $119M | $101M | $111M | $78M | $79M | $77M | $116M | $54M | $52M | $29M | · | $18M | $18M | $12M | $6M | $7M | |
| Inventory | $17M | $16M | $14M | $13M | $12M | $11M | $11M | $10M | $9M | $11M | · | $9M | $9M | $9M | $7M | $5M | |
| Prepaid Expense | $10M | $14M | $14M | $13M | $12M | $15M | $15M | $11M | $7M | $10M | · | $9M | $4M | $4M | $4M | $3M | |
| Other Current Assets | $1M | $1M | $2M | $3M | $3M | $3M | $3M | $1M | $1M | $2M | · | $118.0K | $427.0K | $118.0K | $118.0K | $73.0K | |
| Current Assets | $229M | $226M | $212M | $178M | $155M | $170M | $190M | $147M | $139M | $125M | · | $110M | $60M | $52M | $118M | $64M | |
| PP&E (Net) | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $3M | $3M | · | $4M | $4M | $4M | $3M | $3M | |
| PP&E (Gross) | · | · | $15M | $15M | $15M | $15M | $15M | $15M | $14M | $14M | · | $13M | $13M | $13M | $13M | $12M | |
| Accum. Depreciation | · | · | $12M | $12M | $12M | $11M | $11M | $11M | $11M | $10M | · | $10M | $10M | $9M | $9M | $9M | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | · | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | |
| Intangibles | $176M | $181M | $175M | $172M | $177M | $181M | $185M | $189M | $155M | $157M | · | $163M | $150M | $152M | $24M | $20M | |
| Total Assets | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Accounts Payable | $26M | $26M | $35M | $19M | $23M | $37M | $39M | $25M | $22M | $15M | · | $13M | $18M | $14M | $14M | $14M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $59.0K | · | · | · | · | |
| Short-term Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $102M | $91M | $96M | $65M | $249M | $187M | $91M | $95M | $54M | $42M | · | $19M | $23M | $18M | $19M | $18M | |
| Capital Leases | $7M | $8M | $8M | $8M | $8M | $9M | $9M | $10M | $7M | $7M | · | $7M | $7M | $7M | $7M | $8M | |
| Total Liabilities | $402M | $391M | $347M | $316M | $296M | $308M | $320M | $294M | $248M | $235M | · | $211M | $202M | $196M | $130M | $98M | |
| Long-term Debt | · | $300M | $250M | $347M | $251M | $257M | · | $231M | $236M | $243M | · | $252M | $240M | $244M | · | $98M | |
| Total Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $37.0K | $37.0K | $37.0K | $37.0K | $36.0K | $35.0K | $35.0K | $35.0K | $35.0K | $35.0K | · | $35.0K | $30.0K | $30.0K | $30.0K | $27.0K | |
| Paid-in Capital | $217M | $213M | $209M | $210M | $214M | $226M | $221M | $216M | $212M | $208M | · | $200M | $143M | $138M | $137M | $112M | |
| Retained Earnings | $-201M | $-184M | $-157M | $-163M | $-164M | $-169M | $-151M | $-158M | $-154M | $-147M | · | $-125M | $-120M | $-116M | $-109M | $-111M | |
| Stockholders' Equity | $15M | $29M | $52M | $47M | $50M | $56M | $70M | $58M | $59M | $61M | · | $76M | $22M | $22M | $28M | $1M | |
| Liabilities + Equity | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Shares Outstanding | 37,484,233 | 37,269,400 | 37,229,159 | 37,034,582 | 36,714,679 | 35,654,171 | 35,622,214 | 35,611,365 | 35,479,492 | 35,380,955 | · | 35,117,621 | 30,276,938 | 30,056,370 | 29,901,530 | 27,074,307 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $460.0K | $455.0K | $330.0K | $326.0K | $347.0K | $312.0K | $321.0K | $351.0K | $301.0K | $296.0K | $435.0K | $405.0K | $398.0K | $225.0K | $387.0K | $247.0K | |
| Stock-based Comp | $4M | $4M | $4M | $3M | $875.0K | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $5M | $2M | $2M | $2M | |
| Deferred Tax | · | · | · | · | · | · | · | $20.0K | · | · | · | · | $0 | $-288.0K | · | · | |
| Amort. of Intangibles | $6M | $5M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $3M | $2M | $378.0K | $398.0K | |
| Other Non-cash | · | · | · | · | · | $33M | · | · | · | $4M | · | · | · | · | · | · | |
| Operating Cash Flow | $-10M | $-9M | $8M | $17M | $-803.0K | $20M | $-18M | $3M | $-3M | $-5M | $9M | $-1M | $5M | $-8M | $-4M | $-410.0K | |
| CapEx | $491.0K | $194.0K | $341.0K | $210.0K | $166.0K | $170.0K | $555.0K | $604.0K | $344.0K | $92.0K | $194.0K | $520.0K | $250.0K | $496.0K | $878.0K | $1M | |
| Investing Cash Flow | $-534.0K | $-18M | $-5M | $-225.0K | $-293.0K | $-212.0K | $-38M | $-597.0K | $5M | $-110.0K | $-203.0K | $-20M | $-1M | $-131M | $-5.0K | $-1M | |
| Financing Cash Flow | $-466.0K | $49M | $-5M | $5M | $-13M | $23.0K | $30M | $-721.0K | $73.0K | $-809.0K | $-18.0K | $64M | $189.0K | $62M | $55M | $0 | |
| Net Change in Cash | $-11M | $22M | $-1M | $21M | $-14M | $19M | $-25M | $2M | $2M | $-6M | $8M | $43M | $4M | $-77M | $51M | $-1M | |
| Taxes Paid | · | · | $55.0K | $0 | $0 | $38.0K | · | · | · | · | · | · | · | · | $0 | $35.0K | |
| Free Cash Flow | · | $-9M | · | · | · | $19M | · | · | · | $-5M | · | · | · | $-9M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-13M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.3% | 61.2% | · | 75.3% | 74.5% | 67.5% | · | 75.6% | 74.4% | 69.5% | · | 70.6% | 70.1% | 68.3% | · | 70.5% | |
| Operating Margin | -15.6% | -50.0% | · | 20.6% | 17.9% | -23.5% | · | 2.7% | 3.1% | -20.0% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| Net Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | -37.2% | · | -8.6% | -13.2% | -39.2% | · | -12.8% | -12.6% | -25.4% | · | -28.3% | |
| Pretax Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | · | · | -8.5% | -11.9% | -39.2% | · | -8.3% | -12.7% | -26.6% | · | -28.2% | |
| EBITDA Margin | -15.6% | -50.0% | · | 21.0% | 18.4% | -22.8% | · | 2.7% | 3.1% | -19.2% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| ROA | -4.5% | -7.0% | · | 0.29% | 1.5% | -5.4% | · | -1.3% | -2.4% | -5.3% | · | -2.3% | -2.6% | -4.2% | · | -6.4% | |
| ROE | -53.3% | -64.8% | · | 1.9% | 9.2% | -30.4% | · | -6.3% | -16.0% | -32.9% | · | -11.4% | -30.0% | -41.5% | · | -72.6% | |
| ROIC | -72.4% | -77.0% | · | · | · | · | · | 2.3% | 2.9% | · | · | 3.5% | 10.5% | 5.3% | · | -7.8% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.5 | · | 2.7 | 0.6 | 0.9 | · | 1.5 | 2.6 | 3.0 | · | 5.8 | 2.6 | 2.9 | · | 3.5 | |
| Quick Ratio | 2.0 | 2.1 | · | 2.3 | 0.5 | 0.8 | · | 1.3 | 2.3 | 2.5 | · | 4.9 | 1.1 | 1.1 | · | 3.0 | |
| Debt / Equity | · | · | · | 5.2 | 3.7 | 1.9 | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.3 | · | 0.3 | 0.4 | 0.3 | · | -0.1 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.4 | · | 1.3 | 1.4 | 1.1 | · | 1.4 | 1.5 | 1.2 | · | 1.5 | |
| Receivables Turnover | 0.7 | 0.5 | · | 1.1 | 1.0 | 0.9 | · | 1.4 | 1.4 | 1.7 | · | 2.7 | 2.7 | 2.9 | · | 4.2 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.41 | $0.77 | · | $1.27 | $1.35 | $1.58 | · | $1.63 | $1.65 | $1.71 | · | $2.16 | $0.74 | $0.73 | · | $0.04 | |
| Revenue / Share | $1.89 | $1.19 | · | $1.84 | $1.64 | $1.34 | · | $1.38 | $1.37 | $0.98 | · | $1.00 | $1.10 | $0.86 | · | · | |
| Cash Flow / Share | · | $-0.24 | · | · | · | $0.55 | · | · | · | $-0.13 | · | · | · | $-0.27 | · | · | |
| Cash / Share | $2.24 | $2.54 | · | $2.01 | $1.44 | $1.87 | · | $2.04 | $2.00 | $1.94 | · | $1.87 | · | · | · | $1.66 | |
| EPS (TTM) | $-0.97 | $-0.38 | · | $-0.15 | $-0.30 | $-0.61 | · | $-0.94 | $-0.95 | $-0.91 | · | $-0.44 | $-0.55 | $-0.64 | · | · |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $276M | $269M | · | $250M | $228M | $213M | · | $169M | $154M | $139M | · | $114M | $103M | $93M | · | $88M | |
| Net Income TTM | $-37M | $-15M | · | $-5M | $-10M | $-22M | · | $-33M | $-34M | $-31M | · | $-14M | $-16M | $-18M | · | $-23M | |
| Market Cap | $1.59B | $1.31B | · | $1.78B | $1.12B | $948M | · | $1.60B | $741M | $468M | · | $505M | $576M | $636M | · | $327M | |
| Enterprise Value | · | · | · | $1.95B | $1.25B | $990M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -43.8 | -92.8 | · | -321.2 | -101.8 | -43.6 | · | -47.8 | -22.0 | -14.5 | · | -32.7 | -34.6 | -33.1 | · | · | |
| P/S | 5.8 | 4.9 | · | 7.1 | 4.9 | 4.5 | · | 9.5 | 4.8 | 3.4 | · | 4.4 | 5.6 | 6.9 | · | 3.7 | |
| P/B | 104.7 | 45.8 | · | 38.0 | 22.6 | 16.8 | · | 27.6 | 12.7 | 7.7 | · | 6.7 | 25.7 | 29.1 | · | 268.5 | |
| P / Cash Flow | · | -146.1 | · | · | · | 48.2 | · | · | · | -101.1 | · | · | · | -77.4 | · | · | |
| EV / Revenue | · | · | · | 7.8 | 5.5 | 4.7 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -2.3% | -1.1% | · | -0.31% | -0.98% | -2.3% | · | -2.1% | -4.5% | -6.9% | · | -3.1% | -2.9% | -3.0% | · | · |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $272M | $200M | $130M | $89M | $72M |
| Bruttogewinnmarge % | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% |
| Betriebsgewinnmarge % | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% |
| Nettoergebnis | $-5M | $-17M | $-24M | $-14M | $-18M |
| Verwässerte EPS | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 |
| Quick Ratio | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $43M | $-24M | $2M | $-892.0K | $3M |
Institutionelle Eigentümer (13F) 242 Einreicher · $1.1B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 41 (-6 vs. Vorquartal) | 34 (+4 vs. Vorquartal) | 80 (+11 vs. Vorquartal) | 69 (-9 vs. Vorquartal) | -305K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $116.372.768 | 2.740.117 | 10,90% | Aktien |
| Opaleye Management Inc. | $101.928.000 | 2.400.000 | 9,55% | Aktien |
| VANGUARD GROUP INC | $94.162.467 | 1.921.683 | 8,82% | Aktien |
| Private Capital Management, LLC | $67.899.762 | 1.598.770 | 6,36% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $60.188.994 | 1.417.212 | 5,64% | Aktien |
| Deep Track Capital, LP | $41.153.430 | 969.000 | 3,86% | Aktien |
| STATE STREET CORP | $39.917.043 | 939.888 | 3,74% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $38.466.487 | 905.560 | 3,60% | Aktien |
| BAMCO INC /NY/ | $34.373.094 | 809.350 | 3,22% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31.550.963 | 742.900 | 2,96% | Kaufoption |
| DIMENSIONAL FUND ADVISORS LP | $28.325.286 | 667.036 | 2,65% | Aktien |
| Divisadero Street Capital Management, LP | $18.650.913 | 439.155 | 1,75% | Aktien |
| CITADEL ADVISORS LLC | $16.622.758 | 391.400 | 1,56% | Kaufoption |
| RICE HALL JAMES & ASSOCIATES, LLC | $16.459.036 | 387.545 | 1,54% | Aktien |
| MARSHALL WACE, LLP | $15.689.905 | 369.435 | 1,47% | Aktien |
| CITADEL ADVISORS LLC | $15.283.849 | 359.874 | 1,43% | Aktien |
| NORTHERN TRUST CORP | $13.726.559 | 323.206 | 1,29% | Aktien |
| Schonfeld Strategic Advisors LLC | $13.574.473 | 319.625 | 1,27% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13.531.367 | 318.610 | 1,27% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11.623.869 | 273.696 | 1,09% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $9.998.202 | 235.418 | 0,94% | Aktien |
| CITADEL ADVISORS LLC | $9.895.510 | 233.000 | 0,93% | Verkaufsoption |
| Westside Investment Management, Inc. | $9.515.477 | 224.051 | 0,89% | Aktien |
| FirstWave Capital Management LLC | $9.002.833 | 211.981 | 0,84% | Aktien |
| Blackhawk Capital Partners, LLC | $8.631.645 | 203.241 | 0,81% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $8.074.227 | 190.116 | 0,76% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7.827.221 | 184.300 | 0,73% | Verkaufsoption |
| JANE STREET GROUP, LLC | $7.772.010 | 183.000 | 0,73% | Kaufoption |
| STIFEL FINANCIAL CORP | $7.682.532 | 180.893 | 0,72% | Aktien |
| GOLDMAN SACHS GROUP INC | $6.573.380 | 154.777 | 0,62% | Aktien |
| ROYCE & ASSOCIATES LP | $6.565.310 | 154.587 | 0,62% | Aktien |
| Crawford Fund Management, LLC | $6.035.836 | 142.120 | 0,57% | Aktien |
| Ikarian Capital, LLC | $5.766.364 | 135.775 | 0,54% | Aktien |
| Advantage Alpha Capital Partners LP | $5.374.624 | 111.553 | 0,50% | Aktien |
| MORGAN STANLEY | $5.105.094 | 120.204 | 0,48% | Aktien |
| Diametric Capital, LP | $4.965.082 | 116.908 | 0,47% | Aktien |
| WOODMONT INVESTMENT COUNSEL LLC | $4.748.571 | 111.810 | 0,44% | Aktien |
| BANK OF AMERICA CORP /DE/ | $4.565.398 | 107.497 | 0,43% | Aktien |
| FIRST TRUST ADVISORS LP | $4.260.378 | 100.315 | 0,40% | Aktien |
| STATE OF WISCONSIN INVESTMENT BOARD | $4.146.219 | 97.627 | 0,39% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $3.934.590 | 92.644 | 0,37% | Aktien |
| 12th Street Asset Management Company, LLC | $3.882.140 | 91.409 | 0,36% | Aktien |
| Lumbard & Kellner, LLC | $3.835.975 | 90.322 | 0,36% | Aktien |
| Steward Partners Investment Advisory, LLC | $3.832.960 | 90.251 | 0,36% | Aktien |
| Bank of New York Mellon Corp | $3.625.366 | 85.363 | 0,34% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $3.575.210 | 84.182 | 0,33% | Aktien |
| EQUITABLE TRUST CO | $3.371.184 | 79.378 | 0,32% | Aktien |
| Squarepoint Ops LLC | $3.126.726 | 73.622 | 0,29% | Aktien |
| DEUTSCHE BANK AG\ | $3.009.509 | 70.862 | 0,28% | Aktien |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.004.668 | 70.748 | 0,28% | Aktien |
Aktivisten & 5%+-Eigentümer 5 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Mark L. Baum ×3 Einreichungen | 7. April 2025 | 10,69% | Änderung | · | SEC |
| 27. April 2021 | · | Erste Einreichung | · | SEC | |
| Robert J. Kammer, as Trustee of The Robert J. Kammer Living Trust established 6/1/2000, Robert J. Kammer ×2 Einreichungen | 30. August 2016 | · | Erste Einreichung | Passive Anlage | SEC |
| Dr. Robert J. Kammer ×2 Einreichungen | 16. August 2013 | · | Erste Einreichung | · | SEC |
| DermaStar International, LLC ×7 Einreichungen | 10. August 2012 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 32 Insider · 10 Führungskräfte · 17 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Mark L. Baum | CHIEF EXECUTIVE OFFICER | 14. Mai 2026 P | 2.996.130 | 1 | 0 | $302.000 |
| John P. Saharek | CEO & President, ImprimisRx | 3. April 2025 M | 467.388 | 0 | 0 | $0 |
| Juliet Singh | CEO, Director and President | 18. Juni 2009 A | 1.954.125 | 0 | 0 | $0 |
| Andrew Boll | PRESIDENT AND CFO | 14. Mai 2026 P | 814.679 | 1 | 0 | $104.650 |
| Clayton D Edwards | Chief Operating Officer | 13. April 2017 A | · | 0 | 0 | $0 |
| Amir Shojaei | CHIEF SCIENTIFIC OFFICER | 14. August 2026 M | 0 | 0 | 1 | $-450.000 |
| Patrick William Sullivan | CHIEF COMMERCIAL OFFICER | 30. Januar 2026 A | · | 0 | 0 | $0 |
| Randall E. Pollard | CHIEF ACCOUNTING OFFICER | 1. September 2025 A | · | 0 | 0 | $0 |
| Joachim Ph Schupp | CHIEF MEDICAL OFFICER | 1. April 2013 A | · | 0 | 0 | $0 |
| Terry Nida | Chief Business Officer | 26. Februar 2010 A | · | 0 | 0 | $0 |
| Perry J. Sternberg | Direktor | 18. Juni 2026 A | · | 0 | 0 | $0 |
| Adrienne L Graves | Direktor | 18. Juni 2026 A | 1.000 | 1 | 0 | $31.070 |
| Lauren P Silvernail | Direktor | 18. Juni 2026 A | 1.000 | 1 | 0 | $31.000 |
| Martin A. Makary | Direktor | 14. Juni 2024 A | 45.000 | 0 | 0 | $0 |
| Teresa Sparks | Direktor | 21. Juni 2023 A | · | 0 | 0 | $0 |
| Lawrence R. Van Horn | Direktor | 21. Juni 2023 A | 1.860 | 0 | 0 | $0 |
| Richard L Lindstrom MD | Direktor | 30. September 2022 S | 26.100 | 0 | 0 | $0 |
| Robert J Kammer | Direktor | 25. Juni 2021 A | 797.327 | 0 | 0 | $0 |
| Anthony Principi | Direktor | 28. September 2020 M | 93.798 | 0 | 0 | $0 |
| Stephen G Austin | Direktor | 16. März 2020 M | 91.987 | 0 | 0 | $0 |
| William H. Nelson | Direktor | 10. Juni 2016 A | 12.904 | 0 | 0 | $0 |
| August Shelby Bassani | Direktor | 4. September 2014 A | 13.488 | 0 | 0 | $0 |
| Peter C Kenny | Direktor | 2. Oktober 2013 A | 8.947 | 0 | 0 | $0 |
| Paul Finnegan | Direktor | 27. Juni 2013 A | 6.865 | 0 | 0 | $0 |
| Jeffrey J Abrams | Direktor | 27. Juni 2013 A | 45.927 | 0 | 0 | $0 |
| Opaleye Management Inc. | 10%-Eigentümer | 4. März 2026 S | 59.428 | 0 | 6 | $-9.183.890 |
| Donald Paul Miloni | 10%-Eigentümer | 19. Mai 2015 S | 468.576 | 0 | 0 | $0 |
| DERMASTAR INTERNATIONAL, LLC | 10%-Eigentümer | 12. Juli 2012 J | 0 | 0 | 0 | $0 |
| John N Bonfiglio | · | 20. Oktober 2010 A | 50.000 | 0 | 0 | $0 |
| John T Lomoro | · | 19. Juni 2009 A | · | 0 | 0 | $0 |
| Lynn C Swann | · | 21. November 2008 A | 25.000 | 0 | 0 | $0 |
| Anthony S Thornley | · | 21. November 2008 A | 60.900 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 32 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1,23% | 6.543 NS | 31. Juli 2026 | N-PORT |
| IWC · iShares Trust | 0,28% | 110.031 SH | 11. September 2026 | Täglich |
| IHE · iShares Trust | 0,28% | 122.556 SH | 11. September 2026 | Täglich |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,25% | 82.646 NS | 31. Juli 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,12% | 41.081 NS | 31. Juli 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,08% | 34.722 SH | 19. August 2026 | Täglich |
| FSMD · FIDELITY COVINGTON TRUST | 0,08% | 50.393 NS | 31. Juli 2026 | N-PORT |
| IWO · iShares Trust | 0,08% | 302.749 SH | 11. September 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,08% | 2.662 SH | 2. Oktober 2026 | Täglich |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 7.488 NS | 31. Juli 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 7.406 NS | 31. Juli 2026 | N-PORT |
| RSSL · Global X Funds | 0,04% | 15.475 NS | 31. Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 186.298 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,04% | 826.648 SH | 11. September 2026 | Täglich |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 2.979 SH | 2. Oktober 2026 | Täglich |
| ISCG · iShares Trust | 0,03% | 8.739 SH | 11. September 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,03% | 125.599 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 383.679 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,02% | 94.953 SH | 19. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 15.109 NS | 31. Juli 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 2.287 SH | 11. September 2026 | Täglich |
| DXUV · Dimensional ETF Trust | 0,01% | 949 NS | 31. Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,01% | 61.585 NS | 31. Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 10.408 NS | 31. Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 2.739 NS | 31. Juli 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 11.363 NS | 31. Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 45.401 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 7.042 SH | 4. September 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.001.445 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.637 SH | 19. August 2026 | Täglich |
| ISCB · iShares Trust | · | 1.222 SH | 11. September 2026 | Täglich |
| SMLF · iShares Trust | · | 34.093 SH | 11. September 2026 | Täglich |
HROW Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
12-Monats-Kursziel
9 Analysten · 2026-09-29Mittelwert-Ziel $65.00 +113,3%
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| XERS | $1.30B | · | 43.7% | 0.19% | -19.7% | · |
| KARD | · | · | · | · | · | · |
| OMER | $1.23B | -343.6 | · | · | 1.9% | · |
| AVLN | · | · | · | · | · | · |
| LBRX | $563M | -7.1 | · | · | -25.5% | · |
| YARW | · | · | · | · | · | · |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | · |
| SPTX | · | · | · | · | · | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.